Treatment of Endometriosis Patients with Selective Estrogen Receptor Modulator & Conjugated Estrogen Negatively Impacts Microvascular Function

In: Physiology · 2025 · vol. 40(S1) · doi:10.1152/physiol.2025.40.s1.1102 · W4411875664
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-08-09

Thirty days of Bazedoxifene/Conjugated Estrogen treatment reduced nitric oxide-mediated vasodilation in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Cardiovascular disease (CVD) is the leading cause of death in women. Endometriosis, an estrogen-dependent systemic inflammatory disease, and hot flashes during the menopausal transition are both female-specific risk factors for CVD. Bazedoxifene, a selective estrogen receptor modulator (SERM), with conjugated estrogen (BZE/CE) has been successful in treating menopause-related hot flashes; the SERM protecting breast and uterine tissue from developing abnormalities while the conjugated estrogen is proposed to treat the vasomotor dysfunction. In pre-clinical models of endometriosis BZE/CE has been successful in preventing endometriosis lesions and preliminarily improves endometriosis-related symptoms (i.e., pain) in patients. However, the impact of BZE/CE treatment on the vasculature of women with endometriosis has yet to be investigated. We hypothesized that 30 days of BZE/CE treatment, through estrogen’s vasoprotective actions on the vasculature, would improve vascular endothelial dysfunction, characterized by reduced nitric oxide (NO)-mediated vasodilation, in women with endometriosis. Endometriosis patients (n = 6, 36 ± 9 years) were tested pre-/post-30 days BZE/CE treatment. Two intradermal microdialysis fibers were placed in the forearm. Local heaters and laser-Doppler flowmetry probes were placed over the fibers to record red blood cell flux. Increasing doses of acetylcholine (ACh; log [-10] M to log [-1] M) were perfused to induce endothelium-dependent vasodilation. In one fiber, NO synthase was continuously inhibited with N G -nitro-L-arginine methyl ester (LNAME), while the other perfused ACh alone (Control). Maximal vasodilation was then induced (heat 43ºC + sodium nitroprusside) at each site to allow normalization of cutaneous vascular conductance (CVC; CVC = flux/mean arterial pressure) to site-specific maximums. NO-mediated dilation was calculated as the area between the dose-response curves of the control site and the LNAME site. Flow-mediated dilation (FMD) was used (n = 5) to assess macrovascular endothelial function. Brachial artery diameter was continuously recorded with ultrasound imaging, the artery was occluded for 5 min and then reperfused. FMD is calculated as the % change of brachial artery diameter from baseline to post-occlusion. There was a significant effect of site (p = 0.02) and interaction of site*treatment (p < 0.01). LNAME was significantly lower than the control site during the baseline visit (p < 0.01), and the control site was different following BZE/CE treatment (p = 0.02) while LNAME was not altered after BZE/CE treatment (p = 0.06). LNAME was not different from the control site following BZE/CE treatment (p = 0.29). The NO-mediated dilation was reduced (p = 0.03) from baseline (144 ± 56 AU) after BZE/CE treatment (-83 ± 158 AU). FMD was not altered (6.0 ±2.0% pre-, 6.0 ± 3.3% post- BZE/CE; p = 0.97). These findings indicate that 30 days of BZE/CE treatment induces further microvascular endothelial dysfunction in women with endometriosis. As a SERM, bazedoxifene antagonizes some and agonizes other estrogen receptors. Endometriosis is estrogen-dependent, primarily via estrogen receptor β, and the combined effect of estrogen receptor β agonization and conjugated estrogen delivery may alter systemic inflammation and/or directly impair endothelial function. NIH Grants 1F31HL170616-01 (ACW), R01 HL161000-02S2 (VGC), R01 HL16100 (LMA) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Full text 4,836 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Cardiovascular disease (CVD) is the leading cause of death in women. Endometriosis, an estrogen-dependent systemic inflammatory disease, and hot flashes during the menopausal transition are both female-specific risk factors for CVD. Bazedoxifene, a selective estrogen receptor modulator (SERM), with conjugated estrogen (BZE/CE) has been successful in treating menopause-related hot flashes; the SERM protecting breast and uterine tissue from developing abnormalities while the conjugated estrogen is proposed to treat the vasomotor dysfunction. In pre-clinical models of endometriosis BZE/CE has been successful in preventing endometriosis lesions and preliminarily improves endometriosis-related symptoms (i.e., pain) in patients. However, the impact of BZE/CE treatment on the vasculature of women with endometriosis has yet to be investigated. We hypothesized that 30 days of BZE/CE treatment, through estrogen’s vasoprotective actions on the vasculature, would improve vascular endothelial dysfunction, characterized by reduced nitric oxide (NO)-mediated vasodilation, in women with endometriosis. Endometriosis patients (n = 6, 36 ± 9 years) were tested pre-/post-30 days BZE/CE treatment. Two intradermal microdialysis fibers were placed in the forearm. Local heaters and laser-Doppler flowmetry probes were placed over the fibers to record red blood cell flux. Increasing doses of acetylcholine (ACh; log [-10] M to log [-1] M) were perfused to induce endothelium-dependent vasodilation. In one fiber, NO synthase was continuously inhibited with NG-nitro-L-arginine methyl ester (LNAME), while the other perfused ACh alone (Control). Maximal vasodilation was then induced (heat 43ºC + sodium nitroprusside) at each site to allow normalization of cutaneous vascular conductance (CVC; CVC = flux/mean arterial pressure) to site-specific maximums. NO-mediated dilation was calculated as the area between the dose-response curves of the control site and the LNAME site. Flow-mediated dilation (FMD) was used (n = 5) to assess macrovascular endothelial function. Brachial artery diameter was continuously recorded with ultrasound imaging, the artery was occluded for 5 min and then reperfused. FMD is calculated as the % change of brachial artery diameter from baseline to post-occlusion. There was a significant effect of site (p = 0.02) and interaction of site*treatment (p < 0.01). LNAME was significantly lower than the control site during the baseline visit (p < 0.01), and the control site was different following BZE/CE treatment (p = 0.02) while LNAME was not altered after BZE/CE treatment (p = 0.06). LNAME was not different from the control site following BZE/CE treatment (p = 0.29). The NO-mediated dilation was reduced (p = 0.03) from baseline (144 ± 56 AU) after BZE/CE treatment (-83 ± 158 AU). FMD was not altered (6.0 ±2.0% pre-, 6.0 ± 3.3% post- BZE/CE; p = 0.97). These findings indicate that 30 days of BZE/CE treatment induces further microvascular endothelial dysfunction in women with endometriosis. As a SERM, bazedoxifene antagonizes some and agonizes other estrogen receptors. Endometriosis is estrogen-dependent, primarily via estrogen receptor β, and the combined effect of estrogen receptor β agonization and conjugated estrogen delivery may alter systemic inflammation and/or directly impair endothelial function. NIH Grants 1F31HL170616-01 (ACW), R01 HL161000-02S2 (VGC), R01 HL16100 (LMA) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process. Information & Authors Information Published In Physiology Volume 40 • Issue S1 • May 2025 Copyright Copyright © 2025 Int. Union Physiol. Sci./Am. Physiol. Soc. History Published in print: May 2025 Published online: 12 May 2025

Keyword

Authors Metrics & Citations Metrics Article Usage - For recently published articles, the total views count will show as 0 until a new month begins. - There is a 3–4 day delay in usage data reporting after article publication. - Citation counts are from the Crossref Cited-by service. Altmetrics Dimensions Scite Citations If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click on download. Download article citation data for: Physiology 2025 40:S1 Physiology 2025 40:S1 View Options View options Access content To read the fulltext, please use one of the options below to sign in or purchase access. This functionality works only for purchases made as a guest

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-08-14T06:25:32.811723+00:00
License: CC0 · commercial use OK